Browse by author
Lookup NU author(s): Emeritus Professor Philip Home
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© 2014, The Author(s).Conclusion: Insulin aspart therapy was well tolerated and was associated with improved glucose control over 24 weeks in people with T2DM.Methods: Insulin-naïve and insulin-experienced people with T2DM in routine clinical care starting aspart alone at baseline and continuing aspart alone, changing to biphasic insulin aspart 30 (aspart premix) or adding a basal insulin by study end, were included. Safety, tolerability, and efficacy were evaluated over 24 weeks.Introduction: The aim of the study was to investigate the clinical safety and effectiveness of starting insulin aspart (aspart) therapy in people with type 2 diabetes mellitus (T2DM) as a sub-analysis of the multinational, non-interventional A1chieve study.Results: Overall, 3,898 people started aspart at baseline. Of the 3,313 with 24-week data, 1,545 (46.6%) continued with aspart, 1,379 (41.6%) switched to aspart premix, and 214 (6.5%) added basal insulin, while the remainder switched to other regimens. No serious adverse drug reactions were reported. The proportion of participants reporting hypoglycemia decreased from baseline to week 24 in the aspart alone group (11.2% versus 4.1%, p < 0.001) and in the aspart + basal insulin group (13.1% versus 7.5%, p = 0.040), and was 3.7% at week 24 in the aspart premix group. The mean HbA1c decreased from baseline to week 24 (aspart: −2.1 ± 2.0% [−23 ± 22 mmol/mol], aspart premix: −2.3 ± 1.7% [−25 ± 19 mmol/mol], aspart + basal insulin: −2.0 ± 2.1% [−22 ± 23 mmol/mol]; p < 0.001).
Author(s): Hajjaji I, Shah S, Li Y, Prusty V, Benabbas Y, Home PD
Publication type: Article
Publication status: Published
Journal: Diabetes Therapy
Print publication date: 01/06/2014
Online publication date: 30/01/2014
Acceptance date: 18/12/2013
Date deposited: 29/08/2017
ISSN (print): 1869-6953
ISSN (electronic): 1869-6961
Publisher: Springer Healthcare
Altmetrics provided by Altmetric